Stocks Vertex Pharmaceuticals Inc

  • Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.

  • Winterizing Your Portfolio - A CNBC Special Report

    The Dow shot up more than 100 points Monday after a report showed manufacturing expanded more than expected last month.

  • Stock futures pointed to a modest rebound ahead of the open Monday after the Dow and the S&P 500 experienced their biggest one-day percentage drops Friday since July 2.

  • There’s still a week-and-a-half left in the month, but the markets are currently maintaining yet another month of gains.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.

  • graphic_word_ofthe_street.jpg

    Stocks surrendered earlier gains and fell modestly on Tuesday largely due to fresh worries that major banks may need to raise more money.

  • graphic_fast_money.jpg

    Stocks traded only modestly lower Tuesday, despite concerns that if major banks need to raise more money a financial hurricane may be brewing.

  • Cramer makes the call on viewers' favorite stocks.

  • CNBC's "Power Lunch" team asked some of the best and the brightest from America's big financial firms to list the most promising stocks. Strategists from Citigroup, Goldman Sachs, Cowen & Co. and Deutsche Bank offered CNBC their stock picks.

  • Jamie Dimon

    During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."

  • Will M&A activity boost biotech stocks in 2009?

  • Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.

  • Plus, Cramer make the call on IBM, CSX, Celgene and more.

  • This is how you balance Mad Money stock picks with your own portfolio.

  • This biotech sells its treatment to a niche clientele for big money.

  • Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.

  • Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • schering_plough_earnings.jpg

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...

  • Options activity is picking up in Johnson & Johnson stock. Why?